Search

Search Constraints

You searched for: Author/Creator Yan, Shuling

Search Results

1. 295 First-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas. (9th November 2020)